Tenofovir Disoproxil Fumarate as Pre-Exposure Prophylaxis for HIV Prevention in Women with Osteoporosis: A Case Report and Review of the Literature
Year: 2017
Type: article
Study design: Case Report
Abstract: Pre-exposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF), can effectively prevent HIV acquisition. However, TDF can cause changes in bone mineral density (BMD). There is little information on the use of PrEP among patients with bone disease. We present a case report of a female with pre-existing osteoporosis who was prescribed PrEP. Over the course of 9 months of consistent PrEP use, verified by dried blood spot testing, we report a lack of BMD changes on serial dual-emission X-ray absorptiometry scans in this patient. This case can inform PrEP care for patients with pre-existing bone disease.
Source: Antiviral Therapy
DOI: 10.3851/imp3208
Authors: Rupa R Patel, Rachel Presti, Laura C Harrison, William G Powderly, Philip A Chan
Institutions: Washington University in St. Louis, Brown University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G2202404319, G2824222223, Washington University Institute of Clinical and Translational Sciences, G3887275441, G407586344, PrEP uptake, adherence & retention for African American MSM in Mississippi, Washington University Institute of Clinical and Translational Sciences, G830126741, Washington University Institute of Clinical and Translational Sciences (KL2)
OpenAlex ID: W2770091081